# Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

> **NCT07140679** · PHASE2 · RECRUITING · sponsor: **Emory University** · enrollment: 40 (estimated)

## Conditions studied

- Localized Colon Carcinoma
- Stage IIB Colon Cancer AJCC v8
- Stage IIC Colon Cancer AJCC v8
- Stage III Colon Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Colonoscopy
- **PROCEDURE:** Computed Tomography
- **OTHER:** Questionnaire Administration
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT07140679
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-19
- **Primary completion:** 2029-09-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07140679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07140679, "Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07140679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*